Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance

: Pemovska T, Kylesskiy E, Kontro M, Szwajda A, Karjalainen R, Majumder MM, Malani D, Bespalov MM, Eldfors S, Elonen E, Knowles J, Murumagi A, Mpindi JP, Edgren H, Venkata NPK, Turunen L, Mustjoki S, Wolf M, Yadav B, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K

Publisher: AMER ASSOC CANCER RESEARCH

: 2012

: Cancer Research

: CANCER RESEARCH

: CANCER RES

: 72

: 1

: 0008-5472

DOI: https://doi.org/10.1158/1538-7445.AM2012-895(external)